Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Chile Pharmaceuticals And Healthcare Industry
SWOT — 6
Chile Political SWOT — 7
Chile Economic SWOT — 8
Chile Business Environment
SWOT — 9
Pharmaceutical Business Environment
Ratings — 10
Table: Americas – Regional
Pharmaceutical Business Environment Ratings for Q309 — 10
Limits Of Potential Returns — 11
Risks To Realisation Of
Returns — 11
Chile – Market
Summary — 13
Regulatory Regime — 14
Recent Regulatory Developments — 15
Intellectual
Property — 15
IP Deficiencies — 17
Recent IP Developments — 19
Trade
Agreements — 20
Pricing Regime — 20
Reimbursement Regime — 21
Industry
Developments — 22
Epidemiology — 22
DALYs Lost To All Diseases And Injuries Per 100,00 Population In Select South
American Countries — 22
Healthcare
Sector — 23
Healthcare Insurance — 24
Pharmaceutical Sector — 25
Table: Latin American
Regulations On Bioequivalence And GMP — 26
Domestic
Industry — 27
Foreign Industry — 27
Recent Pharmaceutical Industry Developments — 29
OTC
Medicines — 30
Pharmaceutical Retail
Sector — 31
Clinical Trials — 33
Medical Devices — 33
Industry Forecast
Scenario — 35
Overall Market
Forecast — 35
Table: Chile - Drug Market Expenditure
Indicators, Historical Data and Forecasts — 36
Key Growth
Factors – Industry — 37
Table: Chile - Health
Expenditure Indicators, Historical Data and Forecasts — 38
Key Growth Factors – Macroeconomic — 39
Fiscal
Stimulus to Keep Economy Afloat — 39
Table: Chile -
Economic Activity, 2006-2013 — 42
Prescription Market
Forecast — 43
Table: Chile - Prescription Market
Indicators, Historical Data and Forecasts (CLPmn unless otherwise
stated) — 44
Patented Market
Forecast — 45
Table: Chile - Patented Drug Market
Indicators, Historical Data and Forecasts — 46
Generics
Market Forecast — 47
Generics Market
Forecast — 47
Table: Chile - Generics Drug Market
Indicators, Historical Data and Forecasts — 48
OTC Market
Forecast — 49
Table: Chile - OTC Market Indicators,
Historical Data and Forecasts (CLPmn unless otherwise
stated) — 50
Pharmaceutical Trade
Forecast — 51
Table: Chile - Pharmaceutical Trade
Indicators, Historical Data and Forecasts (US$mn) — 52
Medical Devices Forecasts — 53
Table: Chile - Medical
Device Indicators, Historical Data And Forecasts — 53
Other Healthcare Data — 54
Table: Chile – Other
Healthcare Indicators, Historical Data and Forecasts — 54
Key Risks To BMI’s Forecast Scenario — 54
Competitive Landscape — 56
Company
Monitor — 57
Leading
Multinationals — 57
Pfizer — 57
Novartis — 59
Sanofi-Aventis — 61
Indigenous Companies — 62
Laboratorios Chile
(LabChile) — 62
Country Snapshot: Chile Demographic
Data — 64
Section 1: Population — 64
Table: Demographic Indicators, 2005-2030 — 64
Table:
Rural/Urban Breakdown, 2005-2030 — 65
Section 2: Education
And Healthcare — 65
Table: Education,
2002-2005 — 65
Table: Vital Statistics,
2005-2030 — 65
Section 3: Labour Market And Spending
Power — 66
Table: Employment Indicators,
2001-2006 — 66
Table: Consumer Expenditure, 2000-2012
(US$) — 66
Table: Average Annual Wages,
2000-2012 — 67
BMI Forecast
Modelling — 68
How We Generate Our Pharmaceutical Industry
Forecasts — 68
Pharmaceutical Business Environment Ratings
Methodology — 69
Ratings Overview — 69
Table: Pharmaceutical Business Environment Indicators — 70
Weighting — 71
Table: Weighting Of
Components — 71
Sources — 71
| 
View Cart
